Can Increasing the Number of Close Contact Lead to More  Mortality in COVID-19 Infected Patients?

Hormati, Ahmad; Ghadir, Mohammad Reza; Ghomi, Seyed Yaser Foroghi; Afifian, Mahboubeh; Khodadust, Fatemeh

doi:10.18502/ijph.v49is1.3680

Cited by 4 publications

(5 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have previously reported that reducing close contact is the only effective way to fight the COVID-19 virus ( Hormati, Ghadir, Foroghi Ghomi, et al, 2020 ). As a result, we have attempted to conduct most of our clinical visits virtually and reserve high-risk diagnostic methods only for emergencies.…”

Section: Resultsmentioning

confidence: 99%

“…From February 21 to June 20, 2020, more than 89,000 cases have been diagnosed with COVID-19 in the authors' country of Iran, with 6,150 deaths reported ( Jahangiri, Jahangiri, & Najafgholipour, 2020 ; Nikpouraghdam et al, 2020 ; Shojaee et al, 2020 ). Staying at home or quarantining in an isolated center and minimizing going out are effective ways to battle the spread of COVID-19 ( Aminnejad & Hormati, 2020 ; Hormati, Ghadir, Foroghi Ghomi, et al, 2020 ; Hormati, Ghadir, Zamani, et al, 2020 ; Hormati, Niya, et al, 2020 ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Manifestations of Gastrointestinal Symptoms in COVID-19 Patients

Abbasinia

Hormati

Hossaini

et al. 2021

Gastroenterology Nursing

Self Cite

View full text Add to dashboard Cite

After the outbreak of novel coronavirus disease 2019 (COVID-19) in Wuhan, China, its spread to other countries is rapidly increasing. In this integrative review, we report the prevalence of gastrointestinal symptoms in patients with COVID-19. For this purpose, available articles on gastrointestinal manifestations in patients with COVID-19, which were reported from China, were reviewed. All reviewed articles were searched from December 11, 2019, to June 20, 2020, based on specific key words. Related findings in these articles show that the main target of COVID-19 is lung tissue, as after the virus enters the body, it mainly causes respiratory symptoms in affected patients. But in addition to respiratory symptoms, it is possible that, over time, these patients present with other symptoms, the most obvious of which are gastrointestinal symptoms. It is well documented that diarrhea and vomiting are the most common gastrointestinal symptoms in COVID-19 patients. As part of this report, we also look at the incidence and frequency of gastrointestinal symptoms in COVID-19 patients in Iran. The results can be used by providers as a guideline for better management of gastrointestinal symptoms in these patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Clinical Manifestations of Gastrointestinal Symptoms in COVID-19 Patients

Abbasinia

Hormati

Hossaini

et al. 2021

Gastroenterology Nursing

Self Cite

View full text Add to dashboard Cite

show abstract

“…It has been proposed that the role of the oral cavity as a portal for the entry of the virus into the body and as a viral reservoir can be controlled through the use of antiseptics at two levels. First, by reducing pathogenicity (the decrease in SARS-CoV-2 viral load has been associated with a reduction in the severity of COVID-19) [ 24 , 25 ] and second, by reducing transmission of the virus (by lowering the viral load, the amount of virus shed by the patient may be temporarily reduced, thus reducing the risk of transmission). But the likely impact of daily use of these antiseptics for limited periods of time on viral transmission has not been explored.…”

Section: Introductionmentioning

confidence: 99%

Oral antiseptics against coronavirus: in-vitro and clinical evidence

Mateos-Moreno

Mira

Ausina-Márquez

et al. 2021

Journal of Hospital Infection

View full text Add to dashboard Cite

Background Angiotensin converting enzyme II (ACE2) is the cellular receptor for SARS-CoV-2, so ACE2-expressing cells can act as target cells and are susceptible to infection. ACE2 receptors are highly expressed in the oral cavity so this may be a potential high-risk route for SARS-CoV-2 infection. Furthermore, the virus can be detected in saliva, even before COVID-19 symptoms appear, with the consequent high risk of virus transmission in asymptomatic/pre-symptomatic patients. Reducing oral viral load could lead to a lower risk of transmission via salivary droplets or aerosols and therefore contribute to the control of the pandemic. Aim To evaluate the available evidence testing the in vitro and in vivo effects of oral antiseptics to inactivate or eradicate coronaviruses. Methods The criteria used were those described in the PRISMA® Declaration for performing systematic reviews. An electronic search in MEDLINE (via PubMed) and in Web of Sciences, using the terms MeSH: “mouthwash” OR “oral rinse” OR “mouth rinse” OR “povidone iodine” OR “hydrogen peroxide” OR “cetylpyridinium chloride” AND “COVID-19” OR “SARS-CoV-2” OR “coronavirus” OR “SARS” OR “MERS”. Findings The initial search strategy identified 619 articles on two electronic databases. A total of 17 articles were included assessing the virucidal efficacy of oral antiseptics against coronaviruses. Conclusions There is sufficient in vitro evidence to support the use of antiseptics to potentially reduce the viral load of SARS-CoV-2 and other coronaviruses. However, in vivo evidence for most oral antiseptics is limited. Randomized clinical trials with a control group are needed to demonstrate its clinical efficacy.

show abstract

“…11 Therefore, it is of utmost importance that asymptomatic patients be identified and warnings are given, concerning these carriers to control the epidemic. 12,13 So far, various tests have been developed to confirm the diagnosis of COVID-19. However, some of these methods only have diagnostic potentials for patients with symptoms during the 14 days after contact.…”

Section: Discussionmentioning

confidence: 99%

Production of SARS-CoV-2 Antibodies and Emergence of the Clinical Symptoms of COVID-19

Hormati

Ghadir

Jafari

et al. 2021

IJAAI

Self Cite

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is a worldwide public health problem that has attracted much attention due to its clinical findings. Measurement of IgG and IgM antibodies is of great importance for researchers and it will help to develop a new diagnostic and therapeutic method in clinical care. In this cross-sectional study, we aim to measure the IgG and IgM antibody levels in 401 suspected COVID-19 volunteers. We also measure the time duration for the appearance of IgG and IgM antibodies from the onset of symptoms to sampling time. Of 401 participants enrolled in the study, 255 (63.59%) were healthy, 79 (19.70%) were a carrier, 59 (14.71%) were cured and 8 (1.99%) were borderline. Of 142 subjects diagnosed with COVID-19, 41 (28.87%) presented with gastrointestinal (GI) symptoms, 83 (58.45%) had no GI symptoms, and 18 (12.68%) were asymptomatic. According to our findings, the measurement of IgG and IgM antibodies will provide the tool for the diagnosis of COVID-19 and significantly boost research into novel diagnostic and therapeutic approaches.

show abstract

Can Increasing the Number of Close Contact Lead to More Mortality in COVID-19 Infected Patients?

Abstract: This article is a Letter to the Editor and does not include an Abstract.

Cited by 4 publications

References 5 publications

Clinical Manifestations of Gastrointestinal Symptoms in COVID-19 Patients

Clinical Manifestations of Gastrointestinal Symptoms in COVID-19 Patients

Oral antiseptics against coronavirus: in-vitro and clinical evidence

Production of SARS-CoV-2 Antibodies and Emergence of the Clinical Symptoms of COVID-19

Contact Info

Product

Resources

About